Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

AvePoint Q2 EPS $(3.09), Sales $45.34M Beat $43.65M Estimate

AvePoint (NASDAQ:AVPT) reported quarterly losses of $(3.09) per share. The company reported quarterly sales of $45.34 million which beat the analyst consensus estimate of $43.65 million by 3.88 percent. This is a 37.59
byBenzinga Newsdesk
August 10, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

AvePoint (NASDAQ:AVPT) reported quarterly losses of $(3.09) per share. The company reported quarterly sales of $45.34 million which beat the analyst consensus estimate of $43.65 million by 3.88 percent. This is a 37.59 percent increase over sales of $32.96 million the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

KemPharm’s Earnings: A Preview

By Benzinga Insights
Today, 2:18 AM
KemPharm (NASDAQ:KMPH) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that KemPharm will report an earnings per share (EPS) of $-0.13.

KMPH

Read More

NANOBIOTIX Announced New Data Presented at ASCO Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications

By Charles Gross
Today, 2:18 AM
NANOBIOTIX (Euronext : NANO –– Nasdaq: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the reporting of new data at the 2022 Annual Meeting of the American Society for Clinical Oncology (ASCO) featuring potential first-in-class radioenhancer NBTXR3 in combination wit

NBTX